Skip to main content

Advertisement

SpringerLink
Log in

Allele and genotype frequencies of CYP2B6 in a Turkish population

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Increasing interest in cytochrome P450 2B6 (CYP2B6) genetic polymorphism was stimulated by revelations of a specific CYP2B6 genotype significantly affecting the metabolism of various drugs in common clinical use in terms of increasing drug efficacy and avoiding adverse drug reactions. The present study aimed to determine the frequencies of CYP2B6*4 CYP2B6*5, CYP2B6*6, CYP2B6*7 and CYP2B6*9 alleles in healthy Turkish individuals (n = 172). Frequencies of three single nucleotide polymorphisms were 516G>T (28 %), 785A>G (33 %), and 1459C>T (12 %). The frequencies of CYP2B6*1, *4, *5, *6, *7, and *9 alleles were 54.3 (95 % CI 49.04–59.56), 6.4 % (95 % CI 3.81–8.99), 11 % (95 % CI 7.69–14.31), 25.3 % (95 % CI 20.71–29.89), 0.87 % (95 % CI −0.11–1.85) and 2.0 % (95 % CI 0.52–3.48), respectively. Allele *6 was more frequent (25.3 %) than the other variant alleles in Turkish subjects. The frequencies of CYP2B6*4, *5, *6, *7, and *9 alleles were similar to European populations but significantly different from that reported for Asian populations. This is the first study to document the frequencies of the CYP2B6*4, *5, *6, *7, *9 alleles in the healthy Turkish individuals and our results could provide clinically useful information on drug metabolism by CYP2B6 in Turkish population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hodgson E, Rose RL (2007) The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol Ther 113:420–428

    Article  CAS  PubMed  Google Scholar 

  2. Ekins S, Wrighton SA (1999) The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31:719–754

    Article  CAS  PubMed  Google Scholar 

  3. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V et al (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306

    Article  CAS  PubMed  Google Scholar 

  4. Wang H, Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598–610

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Zanger UM, Hofmann MH (2008) Polymorphic cytochromes P450 CYP2B6 and CYP2D6: recent advances on single nucleotide polymorphisms affecting splicing. Acta Chim Slov 5:38–44

    Google Scholar 

  6. Yamazaki H, Inoue K, Hashimoto M, Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine coxidation by human liver microsomes. Arch Toxicol 73:65–70

    Article  CAS  PubMed  Google Scholar 

  7. Kreth K, Kovar K, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘ecstasy’-related designer drugs. Biochem Pharmacol 59:1563–1571

    Article  CAS  PubMed  Google Scholar 

  8. Hesse L, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI et al (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183

    CAS  PubMed  Google Scholar 

  9. Coller JK, Kregsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T et al (2002) The influence of CYP2B6, CYP2C9, and CYP2D6 genotypes on the formation of the antiestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L et al (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:627–634

    Article  CAS  PubMed  Google Scholar 

  11. Hesse L, He P, Krishnaswamy S, Hao Q, Hogan K, von Molteke LL et al (2004) Pharmacogenetic determinations of interindividual variability in bupropion hydroxylation by cytochrome P4502B6 in human liver microsomes. Pharmacokinetics 14:225–238

    Article  CAS  Google Scholar 

  12. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906–922

    Article  CAS  PubMed  Google Scholar 

  13. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415

    Article  CAS  PubMed  Google Scholar 

  14. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M et al (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34–43

    Article  CAS  PubMed  Google Scholar 

  15. Guengerich FP (1995) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450. Plenum, New York, pp 473–535

    Chapter  Google Scholar 

  16. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW et al (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42

    Article  CAS  PubMed  Google Scholar 

  17. Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, Kalow W, Gelboin HV, McBride OW, Gonzalez F (1989) cDNA cloning and sequence and cDNAdirected expression of human P450IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28:7340–7348

    Article  CAS  PubMed  Google Scholar 

  18. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K et al (2005) A natural CYP2B6 TATA box polymorphism (−82T→C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67:1772–1782

    Article  CAS  PubMed  Google Scholar 

  19. Klein K, Lang T, Saussele T et al (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861–873

    Article  CAS  PubMed  Google Scholar 

  20. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N et al (2003) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398–403

    Article  CAS  PubMed  Google Scholar 

  21. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM et al (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400

    CAS  PubMed  Google Scholar 

  22. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V (2005) Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 40:1358–1361

    Article  CAS  PubMed  Google Scholar 

  23. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL et al (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV infected patients. Pharmacogenet Genomics 15:1–5

    Article  CAS  PubMed  Google Scholar 

  24. Hasse B, Gunthard HF, Bleiber G, Krause M (2005) Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 40:e22–e23

    Article  CAS  PubMed  Google Scholar 

  25. Suzen HS, Yuce N, Guven G, Duydu Y, Erke T (2005) TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol 61:881–885

    Article  CAS  PubMed  Google Scholar 

  26. Suzen HS, Gucyener E, Sakalli O, Uckun Z, Kose G, Ustel D, Duydu Y (2010) CAT C-262T and GPX1 Pro198Leu polymorphisms in a Turkish population. Mol Biol Rep 37:87–92

    Article  CAS  PubMed  Google Scholar 

  27. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985–993

    CAS  PubMed  Google Scholar 

  28. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122–132

    Article  CAS  PubMed  Google Scholar 

  29. Sueyoshi T, Negishi M (2001) Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123–143

    Article  CAS  PubMed  Google Scholar 

  30. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C et al (2004) Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32:348–358

    Article  CAS  PubMed  Google Scholar 

  31. Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525–530

    Article  CAS  PubMed  Google Scholar 

  32. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M et al (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189–197

    Article  CAS  PubMed  Google Scholar 

  33. Desta Z, Saussele T, Ward B et al (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547–558

    Article  CAS  PubMed  Google Scholar 

  34. Kirchheiner J, Klein C, Meineke I et al (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619–626

    Article  CAS  PubMed  Google Scholar 

  35. Chung JY, Jang SB, Lee YJ, Park MS, Park K (2011) Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 51:53–59

    Article  CAS  PubMed  Google Scholar 

  36. Guan S, Huang M, Chan E, Chen X, Duan W, Zhou SF (2006) Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 29:14–21

    Article  CAS  PubMed  Google Scholar 

  37. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y et al (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417–421

    Article  CAS  PubMed  Google Scholar 

  38. Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S (2009) Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug Metab Dispos 37:1991–1993

    Article  CAS  PubMed  Google Scholar 

  39. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA (2006) Prevalence of CYP2B6 alleles in malariaendemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 62:267–275

    Article  PubMed Central  PubMed  Google Scholar 

  40. Arenaz I, Vicente J, Fanlo A, Vasquez P, Medina JC, Conde B, Gonzalez-Andrade F, Sinues B (2010) Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol 24:247–253

    CAS  PubMed  Google Scholar 

  41. Rotger M, Tegude H, Colombo S et al (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557–566

    Article  CAS  PubMed  Google Scholar 

  42. Jacob RM, Johnstone EC, Neville MJ, Walton RT (2004) Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin Chem 50:1372–1377

    Article  CAS  PubMed  Google Scholar 

  43. Ellison CA, Abou El-Ella SS, Tawfik M, Lein PJ, Olson JR (2012) Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A 75:232–241

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Restrepo JG, Martinez C, Garcıa-Agundez A, Gaviria E, Laguna JJ, Elena Garcıa-Martın E, Agundez JAG (2011) Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 21:773–778

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported, in part, by The Scientific and Technological Research Council of Turkey under Project 109S147.

Author information

Authors and Affiliations

  1. Biotechnology Institute, Ankara University, Ankara, Turkey

    Nazan Yuce-Artun

  2. Department of Toxicology, Faculty of Pharmacy, Ankara University, Ankara, Turkey

    Gulcin Kose & H. Sinan Suzen

Authors
  1. Nazan Yuce-Artun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gulcin Kose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Sinan Suzen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Sinan Suzen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yuce-Artun, N., Kose, G. & Suzen, H.S. Allele and genotype frequencies of CYP2B6 in a Turkish population. Mol Biol Rep 41, 3891–3896 (2014). https://doi.org/10.1007/s11033-014-3256-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3256-9

Keywords

Search

Navigation